Singular Genomics launched its fast and flexible mid-throughput sequencing platform, the G4, in the heady days of the pandemic when we saw a renaissance in new technologies and companies. At AGBT earlier this year, the company unveiled its latest offering in development, the G4X Spatial Sequencer, an upgrade to the G4 that unlocks the system to perform high-throughput in situ multiomics.  The platform will be capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics, and fluorescent H&E from FFPE tissues at subcellular resolution. The G4X positions Singular to be the only company worldwide to offer capabilities for tissue-based in situ spatial multiomics and NGS on the same instrument.Singular's CEO, Drew Spaventa, joins us to discuss the G4X platform and the latest evolution in spatial biology.Drew says the field of spatial biology is a billion-dollar market, is growing rapidly, and the platform hits a sweet spot for throughput to bring down running costs. "The biggest issue people have right now in spatial is throughput cost per sample,” says Drew.  “It’s prohibitively expensive.”What early applications does the company see in their early service work?  When will the instrument be available?  And how does Drew see research evolving in the next couple years? This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe